For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Attruby represents a significant breakthrough . These innovative therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the severity of the illness. People are now experiencing positi